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Aim: An attempt was made to assess the impact of following a calorie
restricted diet on the glomerular filtration rate of kidneys and the nutritional state
in the studied group.
Materials and Methodology: Patients with correct body weight and active
kidney transplantation of over three months after the transplantation were
qualified for the study, whereas patients with diagnosed diabetes mellitus and
eating disorders were excluded from it. The patients were divided into two
groups: those adhering to a restricted calorie diet (60 patients) and those with
no diet (41 patients). The diet consisted of 5 meals a day, with the caloricity for
women of approx. 1500 and 2000 kcal in the case of men. The patients ate
meat products once a week and were following the diet for approx. 2 months.
The control group consisted of patients who did not adhere to any diet.
A body composition analysis was conducted by means of bioelectrical
impedance analysis (BIA) and anthropometric measurements. The nutritional
state was described using the BMI (body mass index), the waist to height ratio
(WHtR) as well as the level of albumin and the Nutritional Index (NI). The
excretory function of a transplanted kidney was assessed by calculating the
estimated glomerular filtration rate (eGFR) using the MDRD formula.
Results: In patients who followed the restricted calorie diet, which at the same
time provided all the necessary building and regulatory components, better
glomerular filtration rate was observed compared with patients adhering to the
high calorie diet (p = 0.004). Hypoalbuminaemia and poor nutritional state
(NI < 1.31 points) occurred more frequently in persons who did not have any
diet (p = 0.001).
Conclusions: Rational and balanced diet with restricted calorie intake may
have an impact consisting in an improved glomerular filtration rate and better
well-being. However, in the case of patients with chronic diseases, supervision
of treating physician is necessary.
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Steroids are largely effective for the immunosuppressive treatment in renal
transplant patients, but cause severe side effects.
Objective: To analyze the effect of steroid withdrawal on patient survival in
kidney transplant expanded criteria donors (KTECD)
Material and Methods: A longitudinal, retrospective cohort study, where we
included 335 KTECDs performed between February 1999 and December
2011. Factors associated with patient survival were analyzed.
Results: Patient’s survival at 2, 5 and 7 years was, respectively, 96%, 88%
and 83%. During follow up period (68 months, IR 39-109) 60 patients died
(18%). The most frequent cause of death was infectious (27.9%), followed by
tumoral (26.2%) and cardiovascular (CVC) (23%).
After performing several models adjusted by age, time on dialysis,
cardiovascular disease (CVD), diabetes and propensity scores to receive
steroids, Cox’s multivariate regression analysis showed in the final model, as
risk factors associated to the patient death, the age of the patient (HR 1.1, CI
1.06–1.1, p < 0.001) and post-transplant CVD (HR 2.4, CI 1.1–5.2, p = 0.025),
while the steroid withdrawal was a protective factor (HR 0.2, CI 0.1–0.4,
p < 0.001).
Conclusions: Steroid withdrawal is a protective factor for the patient death in
KTECD. Based on these data, early suspension of steroid therapy could be
suggested in this elderly population with low immunological risk.
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Background: Alport syndrome (AS) is caused by mutations in a3/a4/a5 (IV)
collagen genes, whose severity determines the progression of AS. Post-
transplant outcome is good, though anti-GBM nephritis occurs in 3–5% of
recipients, clustering in patients with a severe mutation
Aim: To assess whether the severity of the underlying AS mutation affects
graft and patient’s outcome after transplantation, including the occurrence of
anti-GBM nephritis
Methods: Retrospective analysis including AS patients with an identified
mutation transplanted between 1972 and 2014. Severe mutations included
truncating, splice-site and non-sense mutations. Missense mutations and in-
frame deletions were considered non-severe.
Results: 73 patients had received 93 kidney grafts: COL4A5 = 57,
COL4A3 = 9, COL4A4 = 6, heterozygous composite COL4A3 and A4 = 1.
Forty-one patients had a severe mutation (COL4A5:30, COL4A3:6, COL4A4:5)
and 32 had a non-severe mutation (COL4A5:27, COL4A3:4; COL4A4:1).
Patient survival was similar in patients with severe and non-severe mutations
(89% vs. 84% at 5 years, 83% vs. 75% at 10, 15 and 20 years (p = 0.46). Graft
survival was not affected by the severity of mutation (77% vs. 63% at 5 years,
60% vs. 55% at 10 years, 55% vs. 55% at 15 years, and 55% vs. 50% at
20 years (p = 0.65). Post-transplant cardiovascular, infectious, neoplastic
complications and acute rejection rate were similar in both groups. Anti-GBM
nephritis occurred in 1 patient with truncating COL4A5 mutation 6 years after
transplantation leading rapidly to graft loss. He developed the same episode
3 years after retransplantation. Of 48 grafts biopsies, linear IgG deposits
without glomerular lesion were observed in 4 grafts (2 severe COL4A5
mutations, 1 severe COL4A4 mutation, 1 missense COL4A5 mutation).
Conclusion: Anti-GBM nephritis occurred in only 1.4% of AS patients and in
2.4% of the subgroup with a severe mutation which is lower than generally
thought. Anti-GBM nephritis may manifest later than previously thought.
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Background: Mycophenolic acid (MA) is prescribed as immunosuppressive
treatment after Kidney Transplantation (KT). MA has been associated with
teratogenicity in rats and women exposed during pregnancy. Recently, the
European Medicines Agency (EMEA) and the Spanish Agency of Medicine and
Sanitary Products (AEMPS) warned about the potential teratogenic effects
even in descendants of males under treatment with MA, so that contraceptives
recommendations should be taken during its consumption. However, there is
no available evidence of malformations in the offspring of males exposed to
MA. Thus, the aim of the present study was to evaluate the incidence of
offspring malformations in KT’s male recipients.
Methods: We conducted a longitudinal and retrospective study in which we
evaluated the incident of descendants’ malformations of 21 KT’s male
recipients that were under treatment with MA before and at the time of
conception.
Results: 28 post-transplant conceptions were identified from 21 KT patients.
MA was used as immunosuppressive medication in 25 out of 28 conceptions.
Whereas 53.6% (n = 15) received Mycophenolate Mofetil, 35.7% (n = 10)
were under Sodium Mycophenolate. The three remaining patients were under
Azathioprine. 11 (58%) patients had had one child, 7 (37%) patients had two
children and 1 (5%) patient had conceived 3 children. Mean age of recipients at
the time of conception was 36.7 ! 4.7. Median time from grafting to conception
was 6 (IQR 2.3–10–7) years. Male or female offspring’s gender percentage
was comparable. 2 miscarriage episodes were recorded in two different
recipients, after which conception was effortlessly accomplished. No malfor-
mation was detected among all offspring at birth or after 5 years of age.
Conclusions: In our study, no evidence of MA-associated malformations was
observed in descendants of males under treatment with MA. Further research
is needed to confirm our findings to properly advice KT recipient males keen to
procreate.
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Background: The renal resistive index (RI) is a sonographic value that is
measured routinely in our hospital in the immediately postoperative period to
monitor recipients of a kidney transplantation. We evaluated whether RI
measured in the immediate post-transplant phase during ICU admission can be
used to predict long-term graft function.
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Methods/Materials: The RI was measured by Doppler ultrasonography in
kidney graft recipients within the first two days after transplantation between
2005 and 2014. Our primary endpoints were eGFR (CKD-EPI) and mortality at
30 days, 1 year and 5 years. The data were retrospectively retrieved from one
tertiary care academic center and 15 peripheral hospitals. Donor, recipient and
outcome variables were retrospectively retrieved from the electronic hospital
database, the laboratory database, DICOM images, the database on intensive
care (Adaptive Server Enterprise), the database of our Transplantation Center,
the Eurotransplant database and local databases of peripheral hospitals.
Results: We included 478 patients, with a median age of 54 years (IQR 45–
62) and with 295 (61.7%) men. Patients had a median follow-up period of
35 months (IQR 19–59, range 0–127). During follow-up, 30 (6.3%) patients
died, of which 27 with a functioning graft. There was no significant correlation
between the RI value and the eGFR at 30 days, 1 year, or 5 years
posttransplant. However, patients who had died at 1 year and 5 years had a
higher RI compared to long-term survivors.
Conclusion: RI, routinely measured the first days after kidney transplanta-
tion, has no correlation with long-term kidney function as measured by eGFR,
but was associated with all-cause mortality at 30 days, 1 year and 5 years.
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Background: The aim of this study was to evaluate the effects on graft
function and survival of BK virus viremia and nephropathy in renal transplant
patients.
Methods and Materials: This study included 2575 renal transplant patients
who were transplanted from living and cadaveric donors in between 2000–
2016 years in our transplant center and divided to two groups. Group 1: BK
virus serum PCR negative 2545 patients (male/female: 1716/829, mean ages
38.2 ! 12.4), Group 2: BK virus viremia and/or BKV associated nephropathy
(BKVAN: %1.2) 30 patients (male/female: 23/7, mean ages: 40.9 ! 12.6).
Tacrolimus, mycophenolic acid derivates (MPA), prednisolone and basiliximab
induction therapy were the most used protocols in group 2 (80%). The
diagnosis of BKVAN and rejection were confirmed by biopsy. Firstly, dose
reduction or end of the MPA (5 patients: %25, 9 patients: %50, 16 patients stop)
and than tacrolimus. Secondly, switched to cyclosporine or everolimus. Thirdly,
cidofovir use in resistant cases. SPSS 20.0 software program was used for
statistical analysis.
Results: Graft survival rates (1./3./5./10. years; %98–90/ %98–80/ %97–80/
96–80, respectively), were lower in the group 2 (p: 0.003, Figure 1), the rates of
acute rejection (16.3–33.3%, p: <0.001), anti-thymocyte globulin uses for
rejection (11.9–13.7%, p: <0.001), cytomegalovirus viremia (1–10%, p: 0.004),
new onset diabetes after transplantation (11.8–50%, p: <0.001), chronic
allograft dysfunction (6.6–46,7%, p: <0.001), serum creatinine levels in last
control (1.38 ! 0.9–1.75 ! 0.6, p: <0.001) were higher in the group 2. In 6 graft
loss patients (3 BKVAN) were used tacrolimus and MPA based regimen.
Serum BKV DNA titers were showed in the Figure 1.
Conclusion: The most effective therapy modalities for BKV viremia and
nephropathy according to our study is the reduction or end of MPA and than
tacrolimus, switched to cyclosporine or especially everolimus in addition to
cidofovir in resistant cases.
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Background: Experience of simultaneous liver transplant combined with
thoracic/cardiac surgery in the UK is extremely limited. There are a number of
reasons for this but with continuing improvements in the technical aspects of
surgery, immunosuppression/graft survival and post-operative care the indi-
cations are likely to expand. We present our experience of simultaneous liver
transplants combined with thoracic/cardiac surgery.
Methods: A retrospective review of all such procedures carried out within our
unit since 1995 were evaluated from available medical notes and electronic
records.
Results: 6 (4M:2F age range 17–56 years) patients underwent combined
procedures. A variety of procedures were performed including Simultaneous
liver and lung (SiLivLunTx) for cystic fibrosis (n = 2), Simultaneous liver and
heart (SiLivHTx) (n = 2) (for familial hypercholesterolemia n = 1 and cardio-
genic cirrhosis following a previous Fontan’s procedure n = 1). A further 2
patients had liver transplantation combined with either an aortic valve
replacement (n = 1) or CABG (n = 1). Two patients received liver re-
transplants one for hepatic artery thrombosis at day 6 and another after
14 years for ductopaenic rejection who also required a pacemaker after a
cardiac arrest following SiLivHTx. 2 patients required endoscopic management
of biliary strictures. Patient mortality at 30 days was 0%. Follow up ranges from
18 months to 20 years during this time 5/6 patients are currently alive and well,
one patient who received SiLivCABG died after 8 years due to cardiac
complications.
Conclusion: Despite the complexities and considerable risks involved, along
with overcoming the logistics of performing 2 major procedures in a single
centre, simultaneous liver transplants performed with major thoracic/cardiac
procedures including either lung or heart transplantation excellent long-term
results can be achieved with zero inpatient mortality even if immediate re-
transplantation is needed.
BOS127 COMBINED LIVER AND PANCREATIC ISLETS
TRANSPLANTATION – IS IT WORTH IT?
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Introduction: Pancreatic islet transplantation (ILTx) can prevent brittle
diabetes (DM) and even achieve insulin independence in some patients.
Transplanted islets may be infused into the portal system during liver
transplantation (LTx), so combined transplantation carries only small additional
risks to LTx.We describe our series of patients with end-stage liver disease and
DM who underwent combined LTx + ILTx at our institution.
Methods: From 2/2007 to 7/2014 six patients underwent combined LTx and
ILTx. Indications for LTx were liver cirrhosis in 4 patients, neuroendocrine liver
metastases and HBV. Indication for ILTx was type 1 DM with zero C-peptide
level and secondary DM after total pancreatectomy in 3 cases. Islets were
isolated from the same donor and were infused into the portal vein intraop-
eratively.
Results: The median number of islets transplanted was 244 000 ieq (range
130 000–482 000 ieq, median number 3330 ieq/kg, range 1510–6600 ieq/kg).
We observed no complication related to islet infusion. All islets grafts exhibited
partial function with median C-peptide and HbA1c levels of 0.27 nmol/l (range
0.05–0.37) and 46 mmol/mol (range 38–57) at 1 year, 0.09 nmol/l (0.02–0.29)
and 48 mmol/mol (41–54) at 2 years and 0.08 nmol/l (0.01–0.45) and
55 mmol/mol (43–63) at 3 years. Two patients died after 42 and 46 months
(liver retransplantation for ischemic cholangiopathy, tumor recurrence) with
partial islets function. Four patients are alive, two with partial islets function (33
and 46 months after ILTx) and two (121 and 115 months after ILTx) with islet
graft failed 46 and 65 months after ILTx. No episodes of severe hypoglycemia
occurred in any of our patients.
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